Dose-Dense Docetaxel versus Weekly Paclitaxel following Dose-Dense Epirubicin and Cyclophosphamide as Adjuvant Chemotherapy in Node-Positive Breast Cancer Patients: A Retrospective Cohort Analysis

METHODS: This study included patients from two prospective studies conducted in our institute from April 2007 to March 2009. Ninety-one women with axillary lymph node-positive breast cancer who had received four cycles of dose-dense epirubicin and cyclophosphamide were treated with either weekly pac...

Descripción completa

Detalles Bibliográficos
Autores principales: Khoshroo, Sara, Sandoughdaran, Saleh, Sabetrasekh, Parisa, Hajian, Parastoo, Bikdeli, Pegah, Sabetrasekh, Parto, Nasrollahi, Fatemeh, Mohammadi Yeganeh, Ladan, Naeini, Sepideh Jafari, Mirzaei, Hamid Reza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8478594/
https://www.ncbi.nlm.nih.gov/pubmed/34594580
http://dx.doi.org/10.1155/2021/6653265
Descripción
Sumario:METHODS: This study included patients from two prospective studies conducted in our institute from April 2007 to March 2009. Ninety-one women with axillary lymph node-positive breast cancer who had received four cycles of dose-dense epirubicin and cyclophosphamide were treated with either weekly paclitaxel (80 mg/m(2)) for 12 doses or biweekly docetaxel (75 mg/m(2)) for four cycles. RESULTS: After a median follow-up of 88 and 109 months, 11 (23.4%) and 10 (22.7%) patients had experienced disease recurrence (p = 0.16), while 10 (21.3%) and 5 (11.4%) patients had died in the paclitaxel and docetaxel arm, respectively (p = 0.56). No significant difference could be seen in 5-year DFS or OS among groups (HR: 0.58; 95% CI: 0.19–1.81, p = 0.35; HR: 0.58; 95% CI: 0.19–1.81, p = 0.35, respectively). CONCLUSION: In conclusion, both evaluated adjuvant chemotherapy regimens have comparable effectiveness regarding DFS and OS.

Ejemplares similares